2-环丙基-2-丙胺 对甲苯磺酸盐

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-环丙基-2-丙胺 对甲苯磺酸盐
• 中文别名: 2-环丙基-2-丙胺对甲苯磺酸盐；2-环丙基-丙基胺-P-TOULUYL盐；Α,Α-二甲基环丙基甲胺对甲苯磺酸盐
• 英文名称: 2-cyclopropyl-2-propylamine toluenesulfonate salt
• 英文别名: 1-cyclopropyl-1-methylethylamine p-toluenesulfonic acid salt；1-cyclopropyl-1-methyl-ethylamine, toluene-4-sulfonate；2-cyclopropyl-2-propylamine-p-toluenesulfonate；2-Cyclopropyl-propylamine-p-toluenesulfonate salt；2-cyclopropylpropan-2-ylazanium;4-methylbenzenesulfonate
• 化学式: C₆H₁₃N*C₇H₈O₃S
• 分子量: 271.381
• InChiKey: RGWMDWPKOOWZSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.38
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  88.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-环丙基-2-丙胺 对甲苯磺酸盐 在 palladium on activated charcoal 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 水 、 乙腈 为溶剂， 反应 26.0h， 生成 Bsmoc-Gln(Dmcp)-OH
  参考文献：
  名称：

  The 1,1-Dioxobenzo[b]thiophene-2-ylmethyloxycarbonyl (Bsmoc) Amino-Protecting Group

  摘要：

  Full details are presented for use of the Bsmoc amino-protecting group for both solid phase and rapid continuous solution syntheses. Application to the latter methodology represents a significant improvement over the corresponding Fmoc-based method for rapid solution synthesis due to the opportunity to use water or saturated sodium-chloride solution rather than an acidic phosphate buffer to remove all byproducts, with consequent cleaner phase separation and higher yields of the growing peptide. Comparison of the Bsmoc and Bspoc functions showed that the former, because of steric hindrance, does not suffer from the competitive or premature deblocking observed with the Bspoc system. Because of its incorporation of a styrene chromophore, resin loading of Bsmoc amino acids could be followed as has previously been shown for the Fmoc analogues. Applications of Bsmoc chemistry to peptide sequences incorporating the base sensitive Asp-Gly unit gave less contamination due to aminosuccinimide formation than comparable syntheses involving standard Fmoc chemistry because a weaker or less concentrated base could be used in the deblocking step. Experimental details are presented for building up peptides in solution via the continuous methodology. Deblockings involved the use of insoluble piperazino silica as well as the polyamine TAEA which simplified aqueous separation of the growing, but nonisolated peptide product, from excess acylating agent and other side products formed in the deblocking process. By the appropriate choice of base, one can act selectively at either site of a molecule which incorporates both beta-elimination and Michael acceptor sites as protective units (Bsmoc vs Fm and Fmoc vs Bsm).

  DOI：

  10.1021/jo982140l

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS
  申请人：Alexander Christopher W.

  公开号：US20100144722A1

  公开（公告）日：2010-06-10

  Novel heterocyclic compounds, sstereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. Additionally, methods of forming novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided.

  提供了式(I)及其立体异构体和/或药学上可接受的盐的新型杂环化合物。此外，还提供了形成新型杂环化合物、其立体异构体和/或药学上可接受的盐的方法。
• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Nelson W. Derek

  公开号：US20080058308A1

  公开（公告）日：2008-03-06

  The present invention relates to thiophene containing compounds of formula (I) wherein R 1 , R 2 , R 3 , and n are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.

  本发明涉及含有式(I)的噻吩类化合物，其中R1、R2、R3和n如规范中定义，包括这种化合物的药物组合物，以及使用这种化合物和药物组合物治疗疾病和疾病的方法。
• SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS
  申请人：Yacovan Avihai

  公开号：US20100056528A1

  公开（公告）日：2010-03-04

  The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents.

  本发明提供公式（I）所定义的磺酰胺类化合物、含有该化合物的药物组合物以及使用这些化合物和药物组合物的治疗方法。这些化合物具有一般广泛的有益治疗指示，特别是作为镇痛和抗炎药物。
• SELECTIVE GRP94 INHIBITORS AND USES THEREOF
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US20160194328A1

  公开（公告）日：2016-07-07

  The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.

  本公开涉及新型选择性Grp94抑制剂，包括含有有效量此类化合物的组合物，以及治疗或预防疾病的方法，例如癌症，包括向需要此类化合物的动物施用有效量此类化合物。
• Selective Grp94 inhibitors and uses thereof
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US10421758B2

  公开（公告）日：2019-09-24

  The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.

  本公开涉及新型选择性 Grp94 抑制剂、包含有效量此类化合物的组合物，以及治疗或预防癌症等疾病的方法，包括向有需要的动物施用有效量的此类化合物。